EUVIMEDEUVIMED entdecken
ValidierungsstudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn’s Disease: A Post Hoc Analysis of the SEAVUE Trial

Dhruv Ahuja, Sama Anvari iD, Emily C L Wong, Parambir Dulai, John K Marshall, Vipul Jairath, Walter Reinisch iD, Neeraj Narula iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izaf137 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Dhruv Ahuja und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Indira Gandhi Hospital, New Delhi, India. Hauptthemen laut MEDLINE: Crohn Disease, Severity of Illness Index, Endoscopy, Gastrointestinal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The modified multiplier of the SES-CD (MM-SES-CD) has been shown to predict future endoscopic healing (EH) in patients with Crohn’s disease. The purpose of this study was to validate baseline MM-SES-CD categories of severity and determine their prognostic value for predicting 1-year EH.

Methods

Participants in the SEAVUE trial (n = 386) were classified based on baseline endoscopic disease severity using MM-SES-CD cut-offs as mild (≥ 22.5 to < 31), moderate (≥ 31 to < 45), and severe (≥ 45) disease. The primary outcome was achieving 1-year endoscopic healing (EH) as measured by the MM-SES-CD score (< 22.5). Secondary outcomes included clinical and biochemical remission at 1 year based on patient-reported outcomes and fecal calprotectin (FCP)(< 250 mcg/g).

Results

MM-SES-CD < 22.5 at 1 year was achieved in 62.0% of patients with baseline mild endoscopic disease, 48.6% with moderate disease, and 33.8% with severe disease (P < .001). A similar trend was observed for patient-reported outcome (PRO-2) clinical remission, which was reached in 78.9% of patients with baseline mild endoscopic disease, 72.9% of those with moderate, and 66.2% of those with severe disease (P = 0.09). The likelihood of fecal calprotectin (FCP) remission was significantly associated with baseline endoscopic disease severity (P = .008).

Conclusion

Baseline MM-SES-CD-based cutoffs for endoscopic disease severity show prognostic value for the likelihood of achieving 1-year EH, PRO2 remission, and FCP remission. These findings suggest that the MM-SES-CD can be used both to measure baseline endoscopic disease severity and predict outcomes at 1 year in patients with moderate to severe CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseSeverity of Illness IndexEndoscopy, GastrointestinalHumansMaleFemaleAdultPrognosisLeukocyte L1 Antigen ComplexRemission InductionMiddle AgedPatient Reported Outcome MeasuresFecesYoung AdultFollow-Up StudiesPredictive Value of Tests

Stichwörter der Autor:innen

Crohn’s diseaseclinical trialsendoscopy

Substanzen

Leukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Department of Medicine, Indira Gandhi Hospital, New Delhi, India.
  • Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, ON, Canada.
  • Division of Gastroenterology, Northwestern University, Chicago, IL, USA.
  • Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada.
  • Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria.

ORCID-Profile: Sama Anvari, Walter Reinisch, Neeraj Narula

Zitieren

APA

Ahuja, D., Anvari, S., Wong, E. C. L., Dulai, P., Marshall, J. K., Jairath, V., Reinisch, W., & Narula, N. (2025). Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn’s Disease: A Post Hoc Analysis of the SEAVUE Trial. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf137

Vancouver

Ahuja D, Anvari S, Wong ECL, Dulai P, Marshall JK, Jairath V, et al. Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn’s Disease: A Post Hoc Analysis of the SEAVUE Trial. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf137

BibTeX
@article{Ahuja2025,
  author = {Ahuja, Dhruv and Anvari, Sama and Wong, Emily C L and Dulai, Parambir and Marshall, John K and Jairath, Vipul and Reinisch, Walter and Narula, Neeraj},
  title = {Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn’s Disease: A Post Hoc Analysis of the SEAVUE Trial},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izaf137}
}
Kostenlos starten →